Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Informatics » New Genomics Company Gets MicroArray Patent

New Genomics Company Gets MicroArray Patent

May 18, 2000
Premium

HAYWARD, Calif.--Biolog, which calls itself a new entrant to the genomics and phenomics fields, has been issued a US patent for a use for its gene-function determination technology, Phenotype MicroArray. Inventor Barry Bochener, Biolog's chairman, said the technology allows simultaneous quantitative measurements of thousands of cellular phenotypes.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Herbert Tabor Dies

The Washington Post reports that Herbert Tabor, who worked at the US National Institutes of Health for 77 years, has died at 101.

Funds to Get Vaccines

The World Bank is seeking approval for a $12 billion plan to provide low-income nations with funds to procure SARS-CoV-2 vaccines, according to Reuters.

A Number on It

Science writes that public health officials and others are debating whether cycle threshold values should be included on SARS-CoV-2 results.

Nucleic Acids Research Studies on 3D SARS-CoV-2 Structures, Human Brain Atlas, More

In Nucleic Acids Research this week: online database of SARS-CoV-2 protein structures, atlas of the human brain, and more.

Oct
01
Featured Webinar

Immune Repertoire Sequencing to Uncover SARS-CoV-2-Specific T Cell Responses and Dynamics

Sponsored by
Adaptive Biotechnologies

T cells are the adaptive immune system’s first responders to any virus, circulating in the blood to detect and quickly multiply to attack the virus, and also support the development of antibodies by B cells. 

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
21
Featured Webinar

Target Enrichment NGS Panel Outperforms the Gold Standard for Sequence and CNV Analysis

Sponsored by
Roche

Target enrichment has been a major driver behind the clinical adoption of next-generation sequencing (NGS) over the last decade because it simplifies analysis and provides a cost-effective method of massive parallel resequencing. It has not only replaced Sanger sequencing, but it is actively dispensing the need for parallel copy number variant (CNV) analysis using classic techniques.

Oct
26
Featured Webinar

Robust CNV Detection Using Whole-Exome Sequencing for Complex Cases

Sponsored by
Sophia Genetics

This webinar will discuss Genotypos Science Labs’ experience with a whole-exome sequencing solution supporting the detection of copy number variants (CNVs) for the management of complex cases.

What's Popular?

In Informatics

  1. Sema4, Janssen Partner on Patient Identification for Cancer Clinical Trials

  2. Catalog DNA Merges Molecular Biology, Information Theory to Pursue DNA-Based Computing

    Premium

  3. Clear Labs Nanopore Sequencing Coronavirus Test Gets FDA Emergency Use Authorization

  4. M2Gen Expands Partnership With Discovery Life Sciences

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.